Carfilzomib shows therapeutic potential for reduction of liver fibrosis by targeting hepatic stellate cell activation

Abstract Because hepatic stellate cells (HSCs) play a major role in fibrosis, we focused on HSCs as a potential target for the treatment of liver fibrosis. In this study, we attempted to identify drug candidates to inactivate HSCs and found that several proteasome inhibitors (PIs) reduced HSC viabil...

Full description

Bibliographic Details
Published in:	Scientific Reports
Main Authors:	Ayana Fujiwara, Keisuke Takemura, Anna Tanaka, Misaki Matsumoto, Masato Katsuyama, Takeshi Okanoue, Kanji Yamaguchi, Yoshito Itoh, Kazumi Iwata, Kikuko Amagase, Atsushi Umemura
Format:	Article
Language:	English
Published:	Nature Portfolio 2024-08-01
Subjects:	Proteasome inhibitor Carfilzomib Hepatic stellate cell Liver fibrosis
Online Access:	https://doi.org/10.1038/s41598-024-70296-8

Similar Items

Drug review: Carfilzomib
by: Prasanth Ganesan
Published: (2019-01-01)

Carfilzomib‐Induced Thrombotic Microangiopathy—Two Case Reports
by: Irene Attucci, et al.
Published: (2024-10-01)

Insulin-Degrading Enzyme Is a Non Proteasomal Target of Carfilzomib and Affects the 20S Proteasome Inhibition by the Drug
by: Grazia Raffaella Tundo, et al.
Published: (2022-02-01)

Carfilzomib in multiple myeloma: unraveling cardiac toxicities - from mechanisms to diagnosis and management
by: Yi Gao, et al.
Published: (2025-03-01)

Carfilzomib induced cardiotoxicity in a multiple myeloma patient
by: Arnold Méndez-Toro, et al.
Published: (2020-09-01)

Balancing the Risk of Cardiotoxicity Outcomes in Treatment Selection for Multiple Myeloma: A Retrospective Multicenter Evaluation of Ixazomib, Lenalidomide, and Dexamethasone (IRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (KRd)
by: Benjamin J. Lee, et al.
Published: (2025-06-01)

Practical Aspects of the Use of Carfilzomib in Multiple Myeloma
by: SV Semochkin, et al.
Published: (2018-12-01)

Real‐world use of carfilzomib combined with lenalidomide and dexamethasone in patients with multiple myeloma in Europe and Israel
by: Xavier Leleu, et al.
Published: (2023-02-01)

Short-Term Proteasome Inhibition: Assessment of the Effects of Carfilzomib and Bortezomib on Cardiac Function, Arterial Stiffness, and Vascular Reactivity
by: Callan D. Wesley, et al.
Published: (2024-10-01)

Carfilzomib in Combination with Bortezomib Enhances Apoptotic Cell Death in B16-F1 Melanoma Cells
by: Min Seung Lee, et al.
Published: (2021-02-01)

Factors determining the sensitivity to proteasome inhibitors of multiple myeloma cells
by: Marta Pelon, et al.
Published: (2024-03-01)

An Untargeted Metabolomics Approach on Carfilzomib-Induced Nephrotoxicity
by: Ioanna Barla, et al.
Published: (2022-11-01)

Carfilzomib activates ER stress and JNK/p38 MAPK signaling to promote apoptosis in hepatocellular carcinoma cells
by: Deng Yao, et al.
Published: (2024-04-01)

New proteasome inhibitors in the management of multiple myeloma
by: S. V. Semochkin
Published: (2019-07-01)

Using protein turnover assay to explore the drug mechanism of Carfilzomib
by: Tao Yonghui, et al.
Published: (2024-07-01)

Daratumumab plus carfilzomib: An optimistic approach in relapsed/refractory multiple myeloma
by: A P Dubey, et al.
Published: (2020-01-01)

Targeting the Proteasome in Advanced Renal Cell Carcinoma: Complexity and Limitations of Patient-Individualized Preclinical Drug Discovery
by: Jielin Li, et al.
Published: (2021-05-01)

Pulmonary toxicity induced by carfilzomib: a case report and review of the literature
by: Mateusz Ziarkiewicz, et al.
Published: (2025-10-01)

Carfilzomib-Induced Thrombotic Microangiopathy Treated with Eculizumab: A Case Report and Rapid Literature Review
by: Federica Pallotti, et al.
Published: (2022-12-01)

Pilot Study: Quantitative Photoacoustic Evaluation of Peripheral Vascular Dynamics Induced by Carfilzomib In Vivo
by: Thi Thao Mai, et al.
Published: (2021-01-01)

Oxyphenbutazone ameliorates carfilzomib induced cardiotoxicity in rats via inhibition of oxidative free radical burst and NF-κB/IκB-α pathway
by: Faisal Imam, et al.
Published: (2024-01-01)

Immunomodulatory Effect of Proteasome Inhibitors via the Induction of Immunogenic Cell Death in Myeloma Cells
by: Maiko Matsushita, et al.
Published: (2023-09-01)

Effective Management of Carfilzomib-Induced Thrombotic Microangiopathy in Multiple Myeloma Using Eculizumab
by: Jennifer Kim, et al.
Published: (2025-06-01)

Pharmacoeconomic evaluation of carfilzomib versus ixazomib for the treatment of relapsed and refractory multiple myeloma
by: Lin Wang, et al.
Published: (2025-12-01)

Carfilzomib Mitigates Lipopolysaccharide/D-Galactosamine/Dimethylsulfoxide-Induced Acute Liver Failure in Mice
by: Dhafer Y. Alhareth, et al.
Published: (2023-11-01)

Carfilzomib induces G2/M cell cycle arrest in human endometrial cancer cells via upregulation of p21Waf1/Cip1 and p27Kip1
by: Yuanyuan Zhou, et al.
Published: (2016-12-01)

Carfilzomib usage patterns and outcomes in patients with relapsed multiple myeloma: A multi‐institutional report from the Canadian Myeloma Research Group (CMRG) Database
by: Arleigh McCurdy, et al.
Published: (2022-11-01)

Histopathological and biochemical profiling of Carfilzomib-loaded Fe–Co MOFs
by: Mohammad Reza Hajinezhad, et al.
Published: (2025-08-01)

Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database
by: Arleigh McCurdy, et al.
Published: (2022-03-01)

Successful treatment with carfilzomib and dexamethasone for relapsed/refractory POEMS syndrome: a case report and review of literature
by: Shuang Yu, et al.
Published: (2025-06-01)

Effects of carfilzomib alone and in combination with cisplatin on the gene expression of Bcl-2 and Bax in ovarian carcinoma cell lines
by: Alireza Saedi, et al.
Published: (2025-03-01)

Belatacept and carfilzomib-based treatment for antibody-mediated rejection in a sensitized nonhuman primate kidney transplantation model
by: Robin Schmitz, et al.
Published: (2023-09-01)

Carfilzomib promotes Iodine-125 seed radiation-induced apoptosis, paraptosis, and ferroptosis in esophageal squamous cell carcinoma by aggravating endoplasmic reticulum stress
by: Chao Wang, et al.
Published: (2025-07-01)

Emodin Ameliorates the Efficacy of Carfilzomib in Multiple Myeloma Cells via Apoptosis and Autophagy
by: Chin-Mu Hsu, et al.
Published: (2022-07-01)

Delayed Onset of Thrombotic Microangiopathy (TMA) upon Prolonged Carfilzomib Therapy in Multiple Myeloma: A Case Report and Comprehensive Review
by: Andrea Ceglédi, et al.
Published: (2024-12-01)

Real‐life effectiveness of carfilzomib in patients with relapsed multiple myeloma receiving treatment in the context of early access: The CARMYN study
by: Kamel Laribi, et al.
Published: (2024-02-01)

Combination effects of Pistachio hull and carfilzomib on NF-κB p65, MDR1, MRP1, and Caspase3 gene expression in breast cancer cell line
by: Zahra Mirzaei, et al.
Published: (2025-01-01)

Machine learning-based nomogram predicts heart failure risk in elderly relapsed/refractory multiple myeloma patients receiving carfilzomib-based therapy
by: Dan Qiao, et al.
Published: (2025-09-01)

Preclinical Evaluation of Carfilzomib for Infant KMT2A-Rearranged Acute Lymphoblastic Leukemia
by: Laurence C. Cheung, et al.
Published: (2021-04-01)

Carfilzomib, lenalidomide, and dexamethasone in relapsed refractory multiple myeloma: a prospective real-life experience of the Regional Tuscan Myeloma Network
by: Elisabetta Antonioli, et al.
Published: (2023-04-01)